{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T04:38:22.935114+00:00","company":{"ticker":"ANEB","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc."},"pagination":{"limit":100,"returned":1,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"85ecc75b300a402e7b5d71d8bc96b284cc55bf32","cik":1815974,"ticker":"ANEB","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"$(0.06) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss ... was $1.7 million, or $(0.06) per share","period_text":"three months ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"Anebulo Pharmaceuticals, Inc. reported three months ended March 31, 2024 results: net income Net loss ... was $1.7 million, or $(0.06) per share, EPS $(0.06) per share.","evidence_excerpt":"today announced financial results for the three months ended March 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-019877","anchor_url":"https://secwatch.observer/filing/0001493152-24-019877#claim-85ecc75b300a402e7b5d71d8bc96b284cc55bf32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/0001493152-24-019877-index.htm"}]}